A growing body of research suggests that combining enzymes with biochar, a carbon-rich material made from agricultural and ...

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...

The newborn screening market offers significant opportunities driven by rising neonatal populations and congenital disease ...

Whether they are laundry detergents, mascara, or Christmas chocolate, many everyday products contain fatty acids from palm ...

Alteogen inks licensing agreement with Tesaro to develop subcutaneous formulation of dostarlimab enabled by Hybrozyme Technology: Daejeon, South Korea Wednesday, January 21, 2026, ...

A growing body of research suggests that combining enzymes with biochar, a carbon-rich material made from agricultural and organic waste, could ...

The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.

Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will ...

A team of agricultural and environmental scientists has developed a simple biochar based technology that can strip self toxic chemicals from pepper ...

A team of agricultural and environmental scientists has developed a simple biochar based technology that can strip self toxic ...

The need to change regulations around gene-editing treatments was endorsed in November by the head of the US Food and Drug ...

Alteogen and Tesaro, a subsidiary of GSK, have entered an exclusive license agreement concerning a subcutaneous formulation of dostarlimab.